Universitaetsklinikum Dresden

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Obesity3 trials
• Lung cancer2 trials
• Acute lymphoblastic leukaemia1 trial
• Atopic dermatitis (eczema)1 trial
• Colorectal cancer1 trial
• Heart failure1 trial
• Myeloproliferative neoplasms1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial
• Type 2 diabetes1 trial

Phase

• Phase 38 trials
• Phase 12 trials

Status

• Active, not recruiting4 trials
• Recruiting3 trials
• Completed1 trial
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Amgen8 trials
• Incyte Corporation1 trial
• Zymeworks BC Inc.1 trial

Running trials

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Amgen· Source

• Recruiting

  A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  NCT07008118· Phase 1· Incyte Corporation· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Amgen· Source

• Active, not recruiting

  Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

  NCT07037433· Phase 3· Amgen· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Active, not recruiting

  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

  NCT06858839· Phase 3· Amgen· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Active, not recruiting

  Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia

  NCT04994717· Phase 3· Amgen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Heart failure1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Terminated

  A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

  NCT06523803· Phase 1· Zymeworks BC Inc.· Source

• Completed

  A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

  NCT05704738· Phase 3· Amgen· Source